Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Fineline Cube Sep 8, 2026
Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Fineline Cube Sep 8, 2026
Company Deals

Smartnuclide Biopharmaceutical Partners with Gosun Pharmaceuticals for rhTSH Market Promotion in China

Fineline Cube Feb 1, 2024

Suzhou Smartnuclide Biopharmaceutical Co., Ltd, a Chinese biopharmaceutical company, has entered into a business cooperation...

Company Deals

MindRank Ltd Partners with Henlius Biotech to Pioneer AI-Powered Drug Therapies

Fineline Cube Feb 1, 2024

MindRank Ltd, a China-based frontier in AI-enabled drug development, has inked a strategic partnership with...

Company Drug

Sandoz Launches Biosimilar Natalizumab in Germany, Challenging Biogen’s Tysabri

Fineline Cube Feb 1, 2024

Sandoz, a division of Novartis and a leader in generic drugs and biosimilars headquartered in...

Company Deals R&D

Siemens Healthineers AG and Shandong First Medical University’s College of Radiology Collaborate on Medical Imaging Metaverse

Fineline Cube Jan 31, 2024

Siemens Healthineers AG (ETR: SHL), a leading life sciences company based in Germany, has entered...

Company

Clinigen Expands Global Footprint with First Fully-Owned Subsidiary in Shanghai’s Free Trade Zone

Fineline Cube Jan 31, 2024

Clinigen, a UK-based medical and pharmaceutical services provider, has announced the establishment of its first...

Company Drug

European Commission Approves Takeda’s Hyqvia for Chronic Inflammatory Demyelinating Polyneuropathy

Fineline Cube Jan 31, 2024

The European Commission (EC) has granted regulatory approval to Takeda Pharmaceutical Company Limited (TYO: 4502)...

Company Deals

WuXi XDC Partners with Multitude Therapeutics and Signs MOU with Shanghai Huilian to Advance ADC Technologies

Fineline Cube Jan 31, 2024

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...

Company

Shanghai Administration Imposes Hefty Fine on H&S Pharmaceutical for Substandard Drugs

Fineline Cube Jan 31, 2024

The Shanghai Municipal Medical Products Administration has disclosed that Hengshan (H&S) Pharmaceutical is under scrutiny...

Company

Shanghai Junshi Biosciences Forecasts 6.02% Revenue Growth in 2023 Driven by Commercialized Products

Fineline Cube Jan 31, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a biopharmaceutical company based in China,...

Company Deals

Regeneron Pharmaceuticals Acquires 2seventy Bio to Boost Cell Therapy Capabilities

Fineline Cube Jan 31, 2024

Regeneron Pharmaceuticals (NASDAQ: REGN) has announced the acquisition of U.S. biotechnology company 2seventy Bio Inc....

Policy / Regulatory

Hunan Province Hospitals Commit to Implementing Nationally Negotiated Drugs in Policy Seminar

Fineline Cube Jan 31, 2024

A policy seminar under the auspices of the Hunan Healthcare Security Administration bureau convened in...

Company

Pfizer Reports USD 58.5 Billion in Revenues Amid Post-Pandemic Sales Shifts and Oncology Pipeline Expansion

Fineline Cube Jan 31, 2024

Pfizer Inc. (NYSE: PFE) has reported a significant downturn in global revenues for the week,...

Company

Astellas Forges Partnership with Mass General Brigham to Boost Oncology and Rare Disease Research

Fineline Cube Jan 31, 2024

Astellas Pharma Inc. (TYO: 4503), a leading Japanese pharmaceutical company, has announced a strategic partnership...

Company Deals

Shanghai CureGene Pharmaceutical Secures USD 14 Million in Series B Financing to Advance Cardiovascular Treatments

Fineline Cube Jan 31, 2024

Shanghai CureGene Pharmaceutical Co., Ltd, a Chinese biopharmaceutical company, has announced the successful completion of...

Company Deals

Ping An Good Doctor Partners with Vcanbio to Pioneer Cell Health Management Services in China

Fineline Cube Jan 31, 2024

Ping An Healthcare and Technology Co., Ltd (HKG: 1833), commonly referred to as PingAn Good...

Company Deals Hospital

Mabwell Bioscience Extends Research Partnership with Fudan University Cancer Center

Fineline Cube Jan 31, 2024

Mabwell (Shanghai) Bioscience Co., Ltd., (SHA: 688062) has announced the renewal of its strategic research...

Company Drug

Hengrui Pharmaceuticals Scores First-Mover Status with FDA Approval for Generic Astagraf XL

Fineline Cube Jan 30, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Deals

Gilead Increases Stake in Arcus Biosciences and Invests in Anti-TIGIT Program

Fineline Cube Jan 30, 2024

Gilead (NASDAQ: GILD) has strengthened its 2020 collaboration agreement with US-based Arcus Biosciences (NYSE: RCUS)...

Company Drug

Takeda’s Gammagard Liquid Approved by FDA for Chronic Inflammatory Demyelinating Polyneuropathy

Fineline Cube Jan 30, 2024

The US Food and Drug Administration (FDA) has granted regulatory approval for Takeda’s (TYO: 4502)...

Company Hospital Policy / Regulatory

Shaanxi Province Unveils Ambitious Three-Year Plan to Boost Traditional Chinese Medicine Industry

Fineline Cube Jan 30, 2024

The provincial government of Shaanxi has unveiled the “Three Year Action Plan for Empowering Shaanxi...

Posts pagination

1 … 458 459 460 … 718

Recent updates

  • Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections
  • China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback
  • Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation
  • CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally
  • Insilico Medicine Partners with Byterna Therapeutics to Build Next‑Generation mRNA AI‑Native R&D Engine – Targeting Circular mRNA Personalized Cancer Vaccines
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Company Deals

Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation

Company Deals

CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.